Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Rituximab in RA (REDOREM)
NCT05116228Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- Sep 2015
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in rheumatoid arthritis (RA), sponsored by Medical University of Vienna. Started Sep 2015; status: terminated.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05116228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05116228.